Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

About IPC

The IPC Impact

  • Educated 1,700 health care providers who attended IPC virtual educational programing

  • Provided more than 30,000 professionals with disease information, medical education, and clinical resources

  • Provided 100 new resources for psoriasis professionals

  • Delivered the IPC monthly Psoriasis Review newsletter to 12,500 individuals

    About IPC

    Our Strategic Plan

    IPC's plan for advancing  knowledge and enhancing  care for patients with psoriasis.


    Latest news

    May 26, 2022
    Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.
    May 16, 2022
    Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.
    May 11, 2022
    IPC Councilor, Ulrich Mrowietz, MD, shares his expert opinion on Cook et al (Br J Dermatol 2022 (online first)) report on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis.
    May 03, 2022
    IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!
    More News


    We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.